Sign up for updates. Be part of our community.

NCI grant will advance Temple leukemia therapeutic towards clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research (SBIR) Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia (AML), to the doorstep of human clinical trials. Read More

Media Contact:

Kristen Fitch

Kristen Fitch

Director, Marketing